Abstract: Antifungal resistance is a topic of concern, particularly for specific fungal species and drugs. Among these are the multidrug-resistant Candida auris and azole-resistant Aspergillus fumigatus. While the knowledge on molecular mechanisms of resistance is now accumulating, further data are also available for the clinical implications and the extent of correlation of in vitro resistance to clinical outcomes. This review article summarizes the epidemiology of C. auris infections, animal models focusing on the activity of novel antifungal compounds in C. auris infections, virulence factors, and the mechanisms of antifungal resistance for this multi-resistant Candida species. Regarding A. fumigatus, the significance of azoles in the treatment of A. fumigatus infections, reference methods available for the detection of resistance in vitro, molecular mechanisms of secondary azole resistance, routes of acquisition, and clinical implications of in vitro resistance are covered to provide guidance for the current status of azole resistance in A. fumigatus.
time on three continents. Similar geographic clustering was observed with Amplified Fragment Length Polymorphism(AFLP) and proteomic analysis of C. auris isolates from three different continents-Asia, Africa, and Latin America [68] . A recent Whole Genome Sequencing (WGS) and single-nucleotide polymorphism (SNP) analysis of C. auris strains isolated in the USA showed multiple introductions of C. auris isolates belonging to the four clades, and spread among healthcare facilities [47] . Most C. auris strains (>60-90%) are resistant to fluconazole, 10-30% exhibit a high minimum inhibitory concentration (MIC) for amphotericin B, and <5% can be considered resistant to echinocandins [28, 69] . Given the recent unprecedented worldwide spread and multidrug resistance, C. auris is included in the world's 10 most feared fungi [70] .
Virulence Factors of C. auris
To determine the virulence properties of C. auris relative to C. albicans, a set of clinical strains were investigated regarding the ability to germinate, adhere, and produce extracellular enzymes [71] . C. auris strains failed to germinate but, in contrast and as expected, C. albicans germinated profusely. Similarly, C. auris exhibited a significantly reduced ability to adhere to silicon elastomer disks relative to C. albicans. Moreover, the C. auris isolates produced phospholipase and proteinase in a strain-dependent manner (37.5% of the C. auris strains possessed phospholipase activity, while 64% evaluated secreted proteinase activity). The last virulence factor evaluated was the ability of C. auris to form biofilms. Our data showed that the formed biofilms were mainly composed of yeast cells, while biofilms formed by C. albicans had a heterogeneous architecture of biofilms comprised of yeast and hyphae morphology embedded within the extracellular matrix. Furthermore, C. auris biofilms had a limited amount of extracellular matrix relative to C. albicans and its biofilm thickness was significantly less than the biofilms formed by C. albicans. Taken together, these data show that C. auris is relatively less pathogenic than C. albicans.
C. auris Animal Models and Activity of Experimental Antifungals
To gain insight into the in vivo virulence of C. auris, an immunosuppressed murine model was developed [72, 73] . Once the model was established it was used to evaluate the efficacy of two experimental antifungals (rezafungin and APX001A). The data showed that rezafungin had a significantly reduced CFUs/g kidneys fungal burden compared with vehicle-or amphotericin B-treated groups. Furthermore, treatment with rezafungin resulted in a significantly lower CFUs/g tissue fungal burden compared to micafungin-treated animals [72] .
Evaluation of the efficacy of APX001 using the optimized immunocompromised mouse model showed that treatment with this experimental drug resulted in a significant increase in animal survival (between 80 and 100% survival in the three treatment groups). In contrast, treatment with anidulafungin led to only a 50% survival rate. In addition, APX001 treatment led to a significant reduction in CFUs/g of kidneys, lung, and brain tissue compared to the vehicle-treated group [73] .
In an immunocompetent murine model, virulence was also highest for C. albicans, closely followed by C. auris, C. glabrata, and C. haemulonii, respectively [74] .
Resistance of C. auris
Besides being antifungal-resistant, C. auris is thermotolerant, grows well up to 42 • C, and is salt-tolerant (up to 10%). These characteristics can be used to design selective media for the detection of C. auris for screening purposes which have been used successfully in outbreak investigations [75] . Concerning resistance to antifungal agents, C. auris has demonstrated extensive resistance to azoles and amphotericin B [24, 28] . The ATP-binding cassette (ABC) transporter activity was significantly higher in C. auris than in C. glabrata [31] . Several genes show encoding of ABC transporters and the important families of C. auris major facilitator superfamily (MFS) genes [76] . An Indian study with a large number of isolates showed that 41% of C. auris from India showed resistance to two antifungal classes and 4% to three antifungal agents [28] . Molecular mechanisms responsible for antifungal resistance point to efflux pumps and mutations in the lanosterol 14-alpha-demethylase (ERG11) gene to explain the high rate of resistance to fluconazole [28, 31] . The latter study demonstrated that 90% of C. auris isolates were resistant to fluconazole (MICs 32 to ≥64 mg/L). ERG11 sequences of resistant C. auris exhibited substitutions of the Y132 and K143 amino acids in 77% of the fluconazole-resistant strains. No substitutions at these positions were observed in isolates with low fluconazole MICs (1-2 mg/L), suggesting that these substitutions confer the fluconazole resistance phenotype similar to that described for C. albicans [77] .
Another study, in a murine model, showed that micafungin was superior compared to fluconazole or amphotericin B, with greater fungicidal activity [78] . These findings make echinocandins the drugs of choice to treat C. auris infections and clinical trials are on their way to explore the therapeutic potential of new drugs.
The combination of antifungals such as voriconazole and echinocandins has been shown to be promising in vitro against resistant C. auris [79] . Although some studies show variable susceptibility of C. auris to the echinocandin class [80] , the good news is that there are new drugs in development with excellent activity against C. auris [71] [72] [73] [81] [82] [83] [84] [85] . SCY-078, a novel orally bioavailable 1,3-β-D-glucan synthesis inhibitor, has been shown to exhibit both in vitro and in vivo activity against C. auris, including some echinocandin-resistant isolates. VT-1598 is another new azole drug with broad activity including C. auris isolates (MIC range 0.03-8 mg/L) [86, 87] .
The cleaning and terminal disinfection of rooms where C. auris-colonized patients have been problematic [61, 88] . Moore et al. [89] showed that chlorine-based disinfectants and iodine-based skin antiseptics were effective against C. auris and reduced environmental contamination and skin colonization. Chlorhexidine-based products may also be effective. Abdolrasouli and collaborators [90] demonstrated that C. auris isolates were inhibited by chlorhexidine gluconate at 0.125-1.5% and by iodinated povidone at a concentration of 0.07-1.25%.
Aspergillus fumigatus

Azole Resistance in A. fumigatus
Aspergillus remains significant as one of the causative agents of invasive infections in immunocompromised individuals and frequently constitutes the most common mold genus isolated in this setting. While voriconazole is the primary drug of choice in the treatment of invasive aspergillosis, the emergence of azole resistance in Aspergillus has been a concern since the first report of secondary resistance of A. fumigatus to itraconazole in 1997 [91, 92] . Antifungal drugs which exert activity against Aspergillus spp. are amphotericin B, triazoles, and echinocandins. Furthermore, triazoles are of particular significance due to the availability of oral formulations. Based on this, triazoles constitute significant therapeutic options for patients with chronic pulmonary aspergillosis and allergic bronchopulmonary aspergillosis who require long-term therapy [93] and azole resistance in A. fumigatus is thus a concern in this respect as well.
Secondary azole resistance in A. fumigatus has been reported from many countries and centers in six continents at extensively varying rates. Similar to those for strains isolated from clinical samples, resistance rates detected for environmental strains are also diverse [94] [95] [96] [97] [98] [99] [100] [101] . The ISHAM/ECMM Aspergillus Resistance Surveillance Working Group aims to facilitate surveillance studies to determine resistance epidemiology in countries where data are currently lacking and provide further insight in terms of clinical implications [102] .
While secondary azole resistance in A. fumigatus draws remarkable attention, the awareness and knowledge on primary antifungal resistance in Aspergillus strains are also increasing. Among the species which are relatively common causes of invasive infections and exhibit primary resistance or reduced susceptibility to one or more antifungal drugs are Aspergillus lentulus (resistance to azoles and amphotericin B and varied susceptibility to caspofungin), Aspergillus flavus (reduced susceptibility to amphotericin B and varied susceptibility to caspofungin), Aspergillus alliaceus (reduced susceptibility to amphotericin B and caspofungin), and Aspergillus terreus (resistance to amphotericin B) [96] .
Detection of Antifungal Resistance In Vitro by Reference Methods
Reference CLSI [103] and EUCAST [104, 105] microdilution susceptibility testing methods are available for testing antifungal drugs against Aspergillus and recommended for routine use [106, 107] . A disk diffusion method of CLSI for testing non-dermatophyte molds and thus applying also to Aspergillus is also available [108] . Epidemiological cut-off values have been determined for the interpretation of the results obtained by the CLSI method [109] [110] [111] [112] , while both epidemiological cut-off values and clinical breakpoints are available for interpreting EUCAST minimum inhibitory concentration values (MIC, mg/L) for some drugs and species [113] . The official reading method for amphotericin B and azole MICs against Aspergillus is visual reading for both CLSI and EUCAST methodologies. A spectrophotometric reading alternative for EUCAST amphotericin B and azole MICs at 5% growth cut-off (vs. complete inhibition of growth visually) proved to be a reliable alternative [105] .
An agar screening method for the detection of secondary azole resistance in A. fumigatus strains has also been validated recently by a multicenter study undertaken by EUCAST [114] . This method uses (in-house or commercially available) 4-well agar plates containing itraconazole (4 mg/L), voriconazole (2 mg/L), and posaconazole (0.5 mg/L); the fourth well serves as the growth control well without any antifungal drug. The ranges of 80-100% and 97-100% were obtained, respectively, for interobserver agreement rate and overall sensitivity. The inter-plate (in-house vs. commercial) agreement rate was high. Similarly, the sensitivity for simulated mixed samples of wild-type and mutant strains and the overall specificity rates also proved to be acceptably high (83-100% and 95-100%, respectively). Based on these data, the assay was validated and is now available as a reference method as documented in EUCAST E.DEF 10.1 [115] . It is an easy and reliable method recommended to be used for routine laboratory work-up, to be followed by reference MIC testing for confirmation in case of the detection of a resistant strain [106] .
Molecular Mechanisms Involved in Secondary Azole Resistance and the Resulting Azole Susceptibility Profiles
Point mutations in the cyp51A gene associated with amino acid changes of M220, G54, G138, G448S, as well as L98H are the most common mechanisms of secondary azole resistance in A. fumigatus. Extra copies of the cyp51A gene (e.g., tandem repeats of a 34-or 46-bp sequence in the promoter of the cyp51A gene) may also accompany specific amino acid changes. The typical examples of this combined pattern are TR34/L98H and TR46/Y121F/T289A [116] . A tandem repeat of 53 bp without any accompanying amino acid change has also been described [117, 118] . In addition, non-cyp51 mutations and increased expression of efflux pumps may play a role in the development of secondary azole resistance. On the other hand, the mechanism remains unknown for a number of isolates. The expected azole susceptibility profiles in relation to the associated amino acid changes and/or tandem repeats are summarized in Table 1 [95, 116] . Table 1 . Expected azole susceptibility profiles with respect to the detected resistance mechanism(s).
Associated Amino Acid
Change/ Tandem Repeat  Resistance  Reduced Susceptibility  Variable Susceptibility Profile   G54  ITC, POS  G138  ITC, POS  G448S  VRC  ITC, POS  M220  ITC  VRC  POS  TR34/L98H *  ITC, VRC, POS, ISV  TR46/Y121F/T289A  VRC  ITC, POS  TR53 ITC, VRC POS ISV: isavuconazole; ITC: itraconazole; POS: posaconazole; VRC: voriconazole; *:
Isolates with TR34/L98H/S297T/F495I changes may have lower minimum inhibitory concentrations (MICs) of voriconazole in the wild-type range. The S297T mutation might be a compensatory mutation in these cases [119, 120] .
Acquisition of Secondary Azole Resistance
There are two mechanisms that play a role in the development of secondary azole resistance in A. fumigatus. First is the (long-term) azole therapy in an individual patient with chronic pulmonary lung disease mostly in existence of a pulmonary cavity, and second is the direct acquisition of a resistant strain from the environment. The latter develops due to the use of azole fungicides (penconazole, difenoconazole, tetraconazole, and tebuconazole) in the environment in agriculture for plant protection [98, 121] . The molecular mechanisms leading to resistance also differ in general for these two routes of acquisition. In the patient-acquired route, M220, G54, and G138 changes are more common while TR34/L98H and TR46/Y121F/T289A patterns are mostly (but not always) observed following environmental acquisition [95, 116] .
Clinical Implications and Current Recommendations for Treatment of Aspergillosis due to Azole-Resistant A. fumigatus
While high azole MICs [122, 123] or the existence of cyp51A mutations [124] were found to be correlated with clinical failure in some studies, other investigators were not able to detect any correlation between MICs and survival rates [125] . This may also emphasize the influence of host factors as well as several others on clinical outcomes in invasive fungal infections observed in immunocompromised individuals. The low rates of resistance, i.e., the low number of infections due to azole-resistant strains included in the analysis, may also render it more difficult to detect any possibly existing in vitro-in vivo correlation. "Strong" or "Moderate" recommendations for the treatment of documented azole-resistant aspergillosis, as included in the recently published ESCMID-ECMM-ERS Guideline [106] , are liposomal amphotericin B monotherapy (Strength of Recommendation (SoR) and Quality of Evidence (QoE): AIIu) and voriconazole and anidulafungin combination (BIII), respectively. Other options with a "Marginal" level of recommendation (CIII for all noted alternatives) include amphotericin B lipid complex monotherapy, posaconazole and caspofungin combination, caspofungin or micafungin monotherapy. The expert opinion, on the other hand, recommends a modification in primary therapeutic choice of voriconazole in case of local environmental resistance rates of >10%. Voriconazole and echinocandin combination or liposomal amphotericin B monotherapy is recommended for initial therapy under these settings [126] .
Concluding Remark
The emerging field of molecular mechanisms of antifungal resistance has been an underestimated area of global public health concern, but significant progress has been made lately in A. fumigatus and C. auris, although research challenges remain formidable. 
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